Under a collaboration and licensing agreement with Dr. Gerry Shaw of the University of Florida and EnCor Biotechnology, Millipore is developing a neurofilament ELISA kit to measure the biomarker pNF-H.

Millipore named Charles Wagner, vice president of Strategy and Corporate Development, CFO, effective August 15.

Meridian Bioscience restructured and expanded its Meridian Life Science subsidiary to include four brands: Biodesign International, Viral Antigens, OEM Concepts and Meridian Biologics.

Invitrogen entered into a global strategic supply and commercialization agreement with Cytori Therapeutics to offer adipose-derived stem cell–based research products.

QIAGEN NV elected Dr. Werner Brandt, CFO of SAP, and Heino von Prondzynski, former CEO of Roche Diagnostics, to its Board, replacing Dr. Franz Wirtz and Dr. Heinrich Hornef.

Whatman entered into a distribution agreement with QIAGEN NV for its FTA and FTA-based kits for DNA collection and storage.

QIAGEN NV expanded its partnership with Epigenomics AG to include exclusive rights to Epigenomics’ technologies for use in applied testing and in vitro molecular diagnostics.

Repligen expanded its relationship with Applied Biosystems, signing a four-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies.

Sigma-Aldrich licensed Epigentek Group’s core technologies, including DNA modification, methylation quantitation and protein/DNA interaction, for exclusive use in the US and coexclusive use outside the US.